Menopause needs a team — not just a gynecologist

Beatriz is 51. She came to the office with a list written by hand, folded three times. Doctor, I went to the gynecologist, she said everything was within the expected range and gave me an antidepressant. I went to the cardiologist, she said my cholesterol went up but it's age. I went to the endocrinologist, she gave me a sleep medication. I'm not better. I'm just taking more things.

I asked for all the labs together on the table. ApoB of 112 mg/dL — climbed 22 points in three years. Fasting glucose 102, basal insulin 14 µIU/mL — was not there in 2022. Waist increased 7 cm. Lumbar spine T-score -1.8 — advanced osteopenia. Estradiol below 20 pg/mL, FSH above 60 — postmenopausal for 18 months. PHQ-9 suggesting mild depressive symptoms. Beatriz does not have three diseases. She has one transition that is manifesting in three systems at the same time.

And she was not poorly attended. Each clinician did what fell within their scope. The problem is that no one looked at the whole Beatriz.

The transition is not a chapter — it is a regime change

Menopause marks the end of cyclical ovarian function. But estrogen did not act only on the cycle. It modulated, in different degrees, the vascular endothelium, insulin sensitivity, bone deposition, temperature regulation, sleep architecture, central neurotransmission, body fat distribution, the lipid profile, and the integrity of the lower urinary tract. When that signal falls, all those systems take the hit — at different rhythms, with different intensities.

The American Heart Association's 2020 scientific statement — signed by El Khoudary and dozens of researchers — synthesized decades of longitudinal follow-up (SWAN, MESA, other cohorts). The conclusion is direct: the menopausal transition is a period of accelerated cardiovascular risk, independent of chronological aging. Increases in total cholesterol and LDL, drop in functional HDL, increase in visceral fat, worsening of arterial stiffness, onset of hypertension — all happen in an interval of 2 to 5 years around the last cycle.

The European consensus document from cardiologists, gynecologists, and endocrinologists, published in the European Heart Journal in 2021, was even more explicit: a postmenopausal woman's cardiovascular health needs to be treated by a team, not by a single specialist working alone. The central symptom — “hot flashes, insomnia, irritability” — is the outside signal. The disease that forms inside is accelerated atherosclerosis, early sarcopenia, bone loss, insulin resistance.

And it is at this moment that the woman usually hears: "it's age."

The systems that reorganize at the same time

Cardiovascular. Average increase of 10 to 15% in LDL and ApoB in the first years after menopause, with the aggravator that particles become more atherogenic (smaller and denser). Systolic blood pressure rises on average 5 mmHg. Heart attack risk, which was about 1/4 of the male risk before, approaches that of men within a decade.

Skeletal. Bone loss accelerates to 2–3% per year in the first 5 years post-menopause. T-score in spine and femur can fall a full standard deviation in that period. Hip fracture after 65 carries one-year mortality comparable to some cancers.

Metabolic. Insulin sensitivity falls 20–30%. Fat distribution migrates from buttocks/thighs to abdomen — visceral fat increases even without weight gain. Type-2 diabetes risk rises.

Cognitive and sleep. Nighttime hot flashes fragment REM and deep sleep. Chronic sleep deprivation + low estrogen = worse executive performance, complaints of “brain fog,” increased long-term risk of cognitive decline. Functional MRI studies show alterations in cerebral glucose metabolism in this phase.

Sexual and urinary. Vulvovaginal atrophy, dyspareunia, recurrent urinary tract infections, urgency. The component most rarely addressed in consultation — the patient rarely brings it up, the physician rarely asks.

Mood. Increased risk of depression, especially in women with prior history. It is not “drama” — it is documented alteration of neurotransmission (serotonin, norepinephrine) and of the HPA axis.

Treating each of these as an isolated problem is like fixing six leaks in six rooms without realizing the main pipe burst.

The hormonal window — what the WHI actually said

Hormone replacement was vilified after the initial publication of the Women's Health Initiative (WHI) in 2002. The press's hasty reading created a generation of physicians afraid to prescribe and a generation of women afraid to receive. What came after — subgroup analyses by age, extended follow-up, reanalyses by time since menopause — painted a much more useful picture.

The long-term WHI follow-up published by Manson and colleagues in JAMA (2017), with 18 years of cumulative follow-up, showed that total mortality did not differ between women treated with hormone therapy and placebo. But the subgroup analysis confirmed what the “timing hypothesis” proposed: women who started therapy between 50 and 59 years old, or in the first 10 years post-menopause, had a reduction in total mortality and coronary disease, with a favorable risk-benefit balance. Women who started late (more than 60 years old, or more than 10 years post-menopause, on arteries that already had established plaque) did not have that benefit and had more risk.

The Mehta, Chester, and Kling review in the Journal of Women's Health (2019) consolidated the concept: there is a window of opportunity — approximately the 5 to 10 years after the last cycle — in which hormone therapy, in women with indication and without contraindication, offers benefit for vasomotor symptoms, bone, urogenital, and probably cardiovascular health, with low risk. Outside that window, the calculus changes.

The decision about replacing or not, with which route, which estrogen, which progestogen, for how long — is not trivial. It requires assessment of individual cardiovascular risk, breast risk, thromboembolic risk, symptoms, quality of life, family history. It is a conversation, not a protocol.

The team that actually works

The usual Brazilian model — isolated gynecologist, cardiologist called after the first event, nutritionist sought on one's own, psychologist in parallel — fails in the menopausal transition by design.

An integrated team for this phase has, at a minimum:

• Internist or gynecologist with training in climacteric and cardiometabolic medicine — coordinates the reading of the whole, decides on hormone replacement, maps cardiovascular risk using ApoB, Lp(a), insulin, hs-CRP, coronary calcium score when indicated.
• Exercise physiologist competent in strength training — because the only intervention proven to maintain bone mass, muscle mass, and insulin sensitivity in this period is progressive overload. Walking is not enough.
• Nutritionist with attention to protein, micronutrients, and body composition — target of 1.4 to 1.6 g/kg/day of protein to preserve lean mass; adjustment of calcium, vitamin D, magnesium, omega-3.
• Psychologist with training in cognitive-behavioral therapy — for mood, sleep, and identity-shift symptoms. CBT has solid evidence for hot flashes when hormone replacement is not an option, and for the common insomnia of this phase.
• Serial bone densitometry and metabolic labs every 6 to 12 months — to follow trend, not snapshot.

This is not luxury. It is reasonable standard of care for a biological turn that defines the next 30 years.

What to order before the next visit

For any woman between 45 and 60, the minimum list is worth the discussion:

• ApoB, Lp(a) (once in a lifetime), full lipid profile
• Fasting insulin, HbA1c, HOMA-IR
• TSH, free T4, free T3
• Estradiol, FSH, SHBG, total and free testosterone
• 25-OH vitamin D, B12, ferritin + transferrin saturation, magnesium
• CBC, kidney and liver function, hs-CRP
• Bone densitometry (DEXA) — baseline at 50, then according to risk
• Coronary calcium score — once, decisive for stratifying the next decade

And — perhaps most importantly — someone willing to look at all those numbers on the same day, with the patient sitting in front, and write a plan, not five referrals.

The reading the Continuum makes

Continuum Plenya was designed precisely for this kind of transition that crosses specialties. Physician, nutritionist, psychologist, and exercise physiologist operate as a single team, with the same updated score, the same clinical meeting every three to six months. Hormone replacement, when indicated, enters as one of the pieces — not as the piece. Strength, protein, sleep, metabolic regulation, mental health — all gain comparable weight in the plan.

Beatriz started transdermal estradiol with micronized progesterone (within the window, no contraindication), began strength training twice a week, adjusted protein to 1.5 g/kg, resumed therapy. In six months, ApoB dropped to 88, fasting glucose 91, hot flashes ceased, deep sleep returned, mood stabilized. It is not that I became another woman, she said. It is that I finally stopped feeling abandoned.

Menopause is not a disease. But it is a transition that reorganizes the entire biology at the same time. Being cared for by a team is not privilege. It is what the complexity of the turn requires.